These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 23105975)
1. Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases. Hristodorov D; Mladenov R; Huhn M; Barth S; Thepen T Toxins (Basel); 2012 Sep; 4(9):676-94. PubMed ID: 23105975 [TBL] [Abstract][Full Text] [Related]
2. Fcgamma receptor 1 (CD64), a target beyond cancer. Thepen T; Huhn M; Melmer G; Tur MK; Barth S Curr Pharm Des; 2009; 15(23):2712-8. PubMed ID: 19689341 [TBL] [Abstract][Full Text] [Related]
3. Recombinant, ETA'-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice. Ribbert T; Thepen T; Tur MK; Fischer R; Huhn M; Barth S Br J Dermatol; 2010 Aug; 163(2):279-86. PubMed ID: 20426788 [TBL] [Abstract][Full Text] [Related]
4. Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies. Hristodorov D; Mladenov R; von Felbert V; Huhn M; Fischer R; Barth S; Thepen T MAbs; 2015; 7(5):853-62. PubMed ID: 26218624 [TBL] [Abstract][Full Text] [Related]
5. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. van Vuuren AJ; van Roon JA; Walraven V; Stuij I; Harmsen MC; McLaughlin PM; van de Winkel JG; Thepen T J Immunol; 2006 May; 176(10):5833-8. PubMed ID: 16670289 [TBL] [Abstract][Full Text] [Related]
6. Resolution of cutaneous inflammation after local elimination of macrophages. Thepen T; van Vuuren AJ; Kiekens RC; Damen CA; Vooijs WC; van De Winkel JG Nat Biotechnol; 2000 Jan; 18(1):48-51. PubMed ID: 10625390 [TBL] [Abstract][Full Text] [Related]
7. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor I-directed immunotoxin. van Roon JA; van Vuuren AJ; Wijngaarden S; Jacobs KM; Bijlsma JW; Lafeber FP; Thepen T; van de Winkel JG Arthritis Rheum; 2003 May; 48(5):1229-38. PubMed ID: 12746896 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin. Jiemy WF; Hiew LF; Sha HX; In LLA; Hwang JS BMC Biotechnol; 2020 Jun; 20(1):31. PubMed ID: 32552895 [TBL] [Abstract][Full Text] [Related]
9. CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases. Akinrinmade OA; Chetty S; Daramola AK; Islam MU; Thepen T; Barth S Biomedicines; 2017 Sep; 5(3):. PubMed ID: 28895912 [TBL] [Abstract][Full Text] [Related]
10. Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages. Hristodorov D; Mladenov R; Fischer R; Barth S; Thepen T Immunol Cell Biol; 2016 May; 94(5):470-8. PubMed ID: 26743033 [TBL] [Abstract][Full Text] [Related]
11. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy. Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313 [TBL] [Abstract][Full Text] [Related]
12. Depletion of synovial macrophages in rheumatoid arthritis by an anti-FcgammaRI-calicheamicin immunoconjugate. van Roon JA; Bijlsma JW; van de Winkel JG; Lafeber FP Ann Rheum Dis; 2005 Jun; 64(6):865-70. PubMed ID: 15539412 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of anti-CD64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice. Zhong RK; van de Winkel JG; Thepen T; Schultz LD; Ball ED J Hematother Stem Cell Res; 2001 Feb; 10(1):95-105. PubMed ID: 11276363 [TBL] [Abstract][Full Text] [Related]
14. FcγRI (CD64): an identity card for intestinal macrophages. De Calisto J; Villablanca EJ; Mora JR Eur J Immunol; 2012 Dec; 42(12):3136-40. PubMed ID: 23255010 [TBL] [Abstract][Full Text] [Related]
15. Macrophages and cutaneous inflammation. McCormick TS; Stevens SR; Kang K Nat Biotechnol; 2000 Jan; 18(1):25-6. PubMed ID: 10625384 [No Abstract] [Full Text] [Related]
16. Immunotoxins and cytokine toxin fusion proteins. Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283 [TBL] [Abstract][Full Text] [Related]
17. Human CD64-targeted non-viral siRNA delivery system for blood monocyte gene modulation. Yong SB; Kim HJ; Kim JK; Chung JY; Kim YH Sci Rep; 2017 Feb; 7():42171. PubMed ID: 28169353 [TBL] [Abstract][Full Text] [Related]
18. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Stahnke B; Thepen T; Stöcker M; Rosinke R; Jost E; Fischer R; Tur MK; Barth S Mol Cancer Ther; 2008 Sep; 7(9):2924-32. PubMed ID: 18790773 [TBL] [Abstract][Full Text] [Related]
19. Immunotoxins in cancer therapy: Review and update. Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218 [TBL] [Abstract][Full Text] [Related]
20. CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo. Mladenov R; Hristodorov D; Cremer C; Gresch G; Grieger E; Schenke L; Klose D; Amoury M; Woitok M; Jost E; Brümmendorf TH; Fendel R; Fischer R; Stein C; Thepen T; Barth S Oncotarget; 2016 Oct; 7(41):67166-67174. PubMed ID: 27564103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]